Title
Evaluation of CD10 expression in prostate adenocarcinoma and its clinic-раthological correlation at tertiary care hospital
Authors
Hukam Singh Meena, Radhika Rai, Aashita Thakur, Shashi Kant, Ashok Panchonia, Meena Mittal & Chandrashekhar Chhatrasal*
Affiliation
Department of Pathology, Mahatma Gandhi Memorial Medical College, Indore, Madhya Pradesh, India; *Corresponding author
Hukam Singh Meena - E-mail: hukammeena44@gmail.com
Radhika Rai - E-mail: drrairadhika@gmail.com
Aashita Thakur - E-mail: aashita.thakur03@gmail.com
Shashi Kant - E-mail: shashiskmc017@gmail.com
Ashok Panchonia - E-mail: drpanchonia@yahoo.co.in
Meena Mittal - E-mail: meenamittal10@gmail.com
Chandrashekhar Chhatrasal - E-mail: drcs_gmc@yahoo.com
Article Type
Research Article
Date
Received June 1, 2026; Revised June 30, 2026; Accepted June 30, 2026, Published June 30, 2026
Abstract
Prostate adenocarcinoma is the second most common cancer in men worldwide and ranks sixth in cancer-related mortality, with more than 95% of cases arising from prostatic acini. CD10, an immunohistochemical marker, has emerged as a potential prognostic indicator, as its high expression is linked to aggressive tumor behavior and early lymph node metastasis, and tumor grading is performed using the WHO Grade Group system based on the Gleason score. Hence, this study included 40 cases of prostate adenocarcinoma diagnosed between January 2023 and December 2024 at the Department of Pathology, MGM Medical College, Indore, involving patients aged 45–95 years with a mean age of 68.5 years. Among the cases evaluated, CD10 expression was negative in 30% (n=12), diffuse in 27.5% (n=11), cytoplasmic in 22.5% (n=9), and membranous in 20% (n=8), and these patterns were correlated with Gleason score. Thus, we show that the pattern of CD10 immunoexpression, particularly diffuse and cytoplasmic positivity, correlates significantly with higher Gleason scores in prostate adenocarcinoma, supporting its incorporation as an adjunct immunohistochemical marker to refine histopathological risk stratification beyond conventional Gleason grading.
Keywords
Prostate cancer, PSA, gleason score, prognostic factors
Citation
Meena et al. Bioinformation 22(6): 3380-3384 (2026)
Edited by
Ritik Kashwani
ISSN
0973-2063
Publisher
License
This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.
